Načítá se...

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in p...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Escudier, Bernard, Cosaert, Jan, Jethwa, Sangeeta
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2008
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721410/
https://ncbi.nlm.nih.gov/pubmed/19707382
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!